Navigation Links
Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
Date:8/1/2013

LAWRENCEVILLE, N.J., Aug. 1, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it would hold a conference call to discuss second quarter 2013 results at 11:00 a.m. EDT on Thursday, August 8, 2013. To participate in the call, interested parties may dial 1-800-723-6498 (Toll-Free/North America) or 1-785-830-7989 (International/Toll) and ask for The Celsion Corporation Second Quarter 2013 Financial Results Conference Call (Conference Code: 3083628) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Thursday, August 8, 2013 at 2:00 p.m. EDT and will remain available until Thursday, August 22, 2013. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 3083628. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2:00 p.m. EDT on Thursday, August 8, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church
Sr. Vice President and Chief Financial Officer
609-482-2455
jchurch@celsion.com


'/>"/>
SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
2. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
3. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
4. Comprehensive Care Corporation Signs Agreement With A National Leader In Pharmacy Benefit Management
5. Luminex Corporation Reports Second Quarter 2013 Results
6. CVS Caremark Corporation To Hold Second Quarter 2013 Conference Call
7. MGC Diagnostics Corporation to Present at the Southern California Investor Conference on Thursday, August 8, 2013
8. FMC Corporation overtar ledende høy-rene Omega-3 konsentratprodusent Epax AS
9. FMC Corporation Acquires Leading High-Purity Omega-3 Concentrates Producer Epax AS
10. Luminex Corporation Achieves Milestone, Ships 10,000th Instrument
11. CVS Caremark Corporation Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):